Federal Minister for Health Mustafa Kamal announced Wednesday that a two-day Pakistan-China health investment conference has yielded 22 formal agreements valued at $629.5 million, marking a significant step in Islamabad's push to expand domestic pharmaceutical manufacturing and attract foreign capital. Main Developments Speaking at a press conference, Kamal detailed that the Pakistan-China Pharmaceutical & Healthcare B2B Investment Conference, held in Islamabad on July 17–18, resulted in agreements spanning vaccine production, active pharmaceutical ingredients (APIs), medical devices, clinical trials, and generic injectables. The event drew 240 Chinese delegates from 140 companies and 430 Pakistani delegates from 210 local firms, making it one of the largest sector-specific bilateral gatherings. Beyond the signed agreements, 84 memorandums of understanding (MoUs) with an estimated combined value of approximately $800 million were also finalized. Kamal noted that many of these MoUs are expected to evolve into binding commercial contracts, driving technology transfer and industrial growth. Read also: Sindh Commission Rejects MQM-P Bid to Release Gul Plaza Fire Report Background Pakistan currently manufactures roughly 85 percent of its medicines locally but imports about 95 percent of the active pharmaceutical ingredients used in production, a vulnerability the government aims to address through this partnership. The country also administers 13 vaccines under its national immunization program, all of which are imported. In response, the government has for the first time developed and approved a National Local Vaccine Production Policy, creating a regulatory framework to support domestic vaccine manufacturing. The deals include two agreements in API manufacturing, eight in vaccine production, two in clinical trials, two in generic formulation injectables, and eight in medical devices. Kamal emphasized that the government's goal is to move beyond MoUs toward legally binding agreements that yield tangible investment and employment. Why It Matters Reducing Pakistan's dependence on imported vaccines and APIs is critical for national health security and economic stability. The new agreements could lower costs, ensure supply chain resilience, and position Pakistan as a regional manufacturing hub. For the pharmaceutical sector, which relies heavily on Chinese raw materials, these deals represent a strategic shift toward vertical integration and value-added production. What's Next The 84 MoUs signed during the conference are expected to undergo due diligence and negotiations, with many anticipated to convert into formal investment agreements. Implementation of the National Local Vaccine Production Policy will proceed alongside these commercial deals, with the government monitoring progress to ensure technology transfer and local employment generation targets are met.